Category: tumor markers

Biomarkers Open New Paths in Cancer Treatment in Greece

Good news for cancer patients in Greece — access to personalized treatments is now becoming a reality.

A recent decision by the Ministry of Health (ΦΕΚ Β’ 5627/20-10-2025, Απόφαση Δ3(α) 41081/2025) approves and reimburses a wider range of biomarker tests, marking an important step forward for modern oncology care.

Read the Government Gazette here

But what are biomarkers?
They are special indicators detected through molecular tests that help doctors understand the unique characteristics of each patient’s cancer. In simple terms, biomarkers act like a “compass,” guiding doctors to choose the most effective and safest treatment for every individual.

Until now, only a few biomarkers were covered by the public health system — for example, molecular signatures that determine whether a woman with early-stage breast cancer needs chemotherapy (approved in 2018), or BRCA1/2 gene tests that reveal inherited risk for breast and ovarian cancer.

The new decision significantly expands this list, adding additional biomarkers for 39 indications. This allows oncologists to tailor treatments to the specific profile of each patient’s tumor, bringing Greece closer to international standards of personalized medicine.

KAPA3, which consistently supports patient education and empowerment, welcomes this development as a vital step toward more human-centred, targeted care.

This progress brings hope, better quality of life, and greater trust in the healthcare system. It is only the beginning, but it lays strong foundations for a future where every patient has access to the right treatment, at the right time.

Learn about patient rights via KAPA3’s extensive library here

Learn more about cancer biomarkers here

Text/Adaptation: Ifiyenia Anastasiou for Kapa3

New limits on diagnostic tests by EOPYY

What applies to oncology patients

With a new decision by the Ministry of Health (Government Gazette 5325/B/2025), stricter rules are in effect for the repetition of diagnostic tests for EOPYY-insured patients, aiming to reduce costs. However, oncology and hematology patients are exempt in many cases, ensuring continuous and uninterrupted medical monitoring.

What changes

  • For a series of laboratory and imaging tests (hematology, biochemistry, hormone tests, tumor markers, ultrasounds, CT, MRI, etc.), it is explicitly stated:
    “Oncology and hematology patients are exempt”, allowing more frequent repetition when justified by the attending physician.

  • For tests such as cancer markers, PET/CT scans, and scintigraphy, the exemption is automatic without time restrictions, as these are part of routine disease monitoring.

  • Oncology patients are also included in the new “Radio-pharmaceutical Reimbursement Procedure”, covering nuclear medicine tests and ensuring full reimbursement.

In summary, for oncology patients, the ability to repeat tests essentially does not change — on the contrary, they are legally protected, as the prescribed exemptions remain.

However, the new framework introduces stricter controls on prescription and reimbursement, which may lead to delays or differences among diagnostic centers and could indirectly affect access and the speed at which tests are carried out.

The full page of the Government Gazette (ΦΕΚ) can be viewed here

Text/adaptation: Ifiyenia Anastasiou for Kapa3